# Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

> **NCT00073593** · PHASE3 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 150 (actual)

## Conditions studied

- Cardiac Surgery
- Coronary Artery Bypass Surgery

## Interventions

- **DRUG:** Bivalirudin
- **DRUG:** Heparin
- **DRUG:** Protamine

## Key facts

- **NCT ID:** NCT00073593
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2004-05
- **Final completion:** —
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2011-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073593, "Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00073593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*